Drugs / SARS-CoV-2 DNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05102643 | Nov 2021 → Jun 2022 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05102643 ↗ |
| Modality | Vaccine | “novel and investigational SARS-CoV-2 DNA vaccine” NCT05102643 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05102643 ↗ |